nodes	percent_of_prediction	percent_of_DWPC	metapath
Terconazole—Bronchospasm—Teniposide—lymphatic system cancer	0.0232	0.0232	CcSEcCtD
Terconazole—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0216	0.0216	CcSEcCtD
Terconazole—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0182	0.0182	CcSEcCtD
Terconazole—Chills—Teniposide—lymphatic system cancer	0.017	0.017	CcSEcCtD
Terconazole—Bronchospasm—Bleomycin—lymphatic system cancer	0.015	0.015	CcSEcCtD
Terconazole—Chills—Fludarabine—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Terconazole—Face oedema—Carmustine—lymphatic system cancer	0.0148	0.0148	CcSEcCtD
Terconazole—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Terconazole—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Terconazole—Malaise—Fludarabine—lymphatic system cancer	0.013	0.013	CcSEcCtD
Terconazole—Pruritus—Mechlorethamine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Terconazole—Arthralgia—Fludarabine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Terconazole—Myalgia—Fludarabine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Terconazole—Discomfort—Fludarabine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Terconazole—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Terconazole—Vomiting—Mechlorethamine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Terconazole—Rash—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Terconazole—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Terconazole—Feeling abnormal—Teniposide—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Terconazole—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.011	0.011	CcSEcCtD
Terconazole—Chills—Bleomycin—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Terconazole—Nausea—Mechlorethamine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Terconazole—Urticaria—Teniposide—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Terconazole—Abdominal pain—Teniposide—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Terconazole—Body temperature increased—Teniposide—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Terconazole—Pain—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Terconazole—Hypersensitivity—Teniposide—lymphatic system cancer	0.0099	0.0099	CcSEcCtD
Terconazole—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00984	0.00984	CcSEcCtD
Terconazole—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00973	0.00973	CcSEcCtD
Terconazole—Asthenia—Teniposide—lymphatic system cancer	0.00964	0.00964	CcSEcCtD
Terconazole—Malaise—Bleomycin—lymphatic system cancer	0.00956	0.00956	CcSEcCtD
Terconazole—Pruritus—Teniposide—lymphatic system cancer	0.0095	0.0095	CcSEcCtD
Terconazole—Body temperature increased—Fludarabine—lymphatic system cancer	0.00933	0.00933	CcSEcCtD
Terconazole—Myalgia—Bleomycin—lymphatic system cancer	0.00903	0.00903	CcSEcCtD
Terconazole—Discomfort—Bleomycin—lymphatic system cancer	0.00892	0.00892	CcSEcCtD
Terconazole—Chills—Mitoxantrone—lymphatic system cancer	0.00887	0.00887	CcSEcCtD
Terconazole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0087	0.0087	CcSEcCtD
Terconazole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00866	0.00866	CcSEcCtD
Terconazole—Vomiting—Teniposide—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Terconazole—Asthenia—Fludarabine—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Terconazole—Rash—Teniposide—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Terconazole—Dermatitis—Teniposide—lymphatic system cancer	0.00846	0.00846	CcSEcCtD
Terconazole—Headache—Teniposide—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Terconazole—Pruritus—Fludarabine—lymphatic system cancer	0.00835	0.00835	CcSEcCtD
Terconazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00799	0.00799	CcSEcCtD
Terconazole—Nausea—Teniposide—lymphatic system cancer	0.00798	0.00798	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Terconazole—Myalgia—Carmustine—lymphatic system cancer	0.00788	0.00788	CcSEcCtD
Terconazole—Malaise—Mitoxantrone—lymphatic system cancer	0.00776	0.00776	CcSEcCtD
Terconazole—Myalgia—Vincristine—lymphatic system cancer	0.00752	0.00752	CcSEcCtD
Terconazole—Vomiting—Fludarabine—lymphatic system cancer	0.00751	0.00751	CcSEcCtD
Terconazole—Rash—Fludarabine—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Terconazole—Dermatitis—Fludarabine—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Terconazole—Pain—Bleomycin—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Terconazole—Headache—Fludarabine—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Terconazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Terconazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Terconazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.00724	0.00724	CcSEcCtD
Terconazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Terconazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00713	0.00713	CcSEcCtD
Terconazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Terconazole—Nausea—Fludarabine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Terconazole—Urticaria—Bleomycin—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Terconazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.00684	0.00684	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Terconazole—Pain—Carmustine—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Terconazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00641	0.00641	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Terconazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Terconazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Terconazole—Asthenia—Bleomycin—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Terconazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Terconazole—Pain—Vincristine—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Terconazole—Pruritus—Bleomycin—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Terconazole—Pain—Mitoxantrone—lymphatic system cancer	0.00601	0.00601	CcSEcCtD
Terconazole—Abdominal pain—Carmustine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Terconazole—Body temperature increased—Carmustine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Terconazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Terconazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Terconazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Terconazole—Abdominal pain—Vincristine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Terconazole—Body temperature increased—Vincristine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Terconazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Terconazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Terconazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Terconazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Terconazole—Vomiting—Bleomycin—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Terconazole—Rash—Bleomycin—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Terconazole—Dermatitis—Bleomycin—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Terconazole—Asthenia—Carmustine—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Terconazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Terconazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Terconazole—Asthenia—Vincristine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Terconazole—Nausea—Bleomycin—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Terconazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Terconazole—Dizziness—Carmustine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Terconazole—Vomiting—Carmustine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Terconazole—Dizziness—Vincristine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Terconazole—Rash—Carmustine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Terconazole—Dermatitis—Carmustine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Terconazole—Headache—Carmustine—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Terconazole—Vomiting—Vincristine—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Terconazole—Rash—Vincristine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Terconazole—Dermatitis—Vincristine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Terconazole—Headache—Vincristine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Terconazole—Nausea—Carmustine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Terconazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Terconazole—Rash—Mitoxantrone—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Terconazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Terconazole—Chills—Methotrexate—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Terconazole—Headache—Mitoxantrone—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Terconazole—Nausea—Vincristine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Terconazole—Nausea—Mitoxantrone—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Terconazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Terconazole—Malaise—Methotrexate—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Terconazole—Myalgia—Methotrexate—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Terconazole—Arthralgia—Methotrexate—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Terconazole—Discomfort—Methotrexate—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Terconazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Terconazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Terconazole—Pain—Methotrexate—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Terconazole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Terconazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Terconazole—Urticaria—Methotrexate—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Terconazole—Abdominal pain—Methotrexate—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Terconazole—Body temperature increased—Methotrexate—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Terconazole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Terconazole—Asthenia—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Terconazole—Pruritus—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Terconazole—Dizziness—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Terconazole—Vomiting—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Terconazole—Rash—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Terconazole—Dermatitis—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Terconazole—Headache—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Terconazole—Nausea—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
